View Older Stories View More Recent Stories

Feb 14, 2025 04:50PM Form SCHEDULE 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2025 03:20PM Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
Feb 11, 2025 08:04AM TruBridge (TBRG) Announces Two Directors to Join Its Board as a Part of Cooperation Agreements With Pinetree Capital and Ocho Investments
Jan 31, 2025 07:19PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Jan 31, 2025 07:18PM Form 144 BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:33PM Form SC 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:32PM Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:33PM Form SC 13G/A Tourmaline Bio, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:32PM Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:32PM Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:32PM Form SC 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:31PM Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:31PM Form SC 13G/A Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2024 04:01PM Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
Nov 6, 2024 05:04PM Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 6, 2024 05:04PM Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
Oct 4, 2024 07:38AM Form D/A Viking Global Opportunit
Oct 4, 2024 07:35AM Form D/A Viking Global Opportunit
Oct 4, 2024 07:33AM Form D/A Viking Global Equities
Oct 4, 2024 07:30AM Form D/A Viking Global Equities
Oct 4, 2024 07:03AM Form D/A Viking Global Equities
Sep 30, 2024 04:29PM Form SC 13G BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
Sep 3, 2024 04:11PM Form N-PX VIKING GLOBAL INVESTORS For: Jun 30
Aug 20, 2024 08:42PM Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Aug 14, 2024 04:17PM Form 13F-HR VIKING GLOBAL INVESTORS For: Jun 30
Jul 15, 2024 04:18PM Form SC 13G Longboard Pharmaceutical Filed by: VIKING GLOBAL INVESTORS LP
Jun 18, 2024 05:06PM Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
Jun 7, 2024 04:24PM Form SC 13G Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP
Jun 3, 2024 05:56PM Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Jun 3, 2024 02:30PM Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2024 08:00AM Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
May 25, 2024 06:51AM HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
May 24, 2024 07:02AM HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
May 23, 2024 08:17AM Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024 09:00AM Pearl Health releases Top 50 Value-Based Care Thinkers of 2024
May 22, 2024 07:31AM Biogen (BIIB) to Acquire Human Immunology Biosciences for $1.15B Upfront Plus Milestone Payments
May 22, 2024 07:30AM Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 15, 2024 07:26PM Hedge fund Coatue scraps its Apple stake in Q1, while Viking built its position
May 15, 2024 04:06PM Form 13F-HR VIKING GLOBAL INVESTORS For: Mar 31
May 9, 2024 12:00PM With Vim as a Strategic Technology Partner, Pearl Health Launches Enhanced EHR Experience
May 8, 2024 09:49AM AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc
May 7, 2024 04:05PM AbCellera Reports Q1 2024 Business Results
May 1, 2024 09:00AM AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
May 1, 2024 07:00AM Ayana Bio Awarded National Institutes of Health Grant to Harness Neuroprotective Benefits from Plant Cell-Cultivated Saffron
Apr 30, 2024 10:00AM Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics
Apr 12, 2024 10:54AM Revive Environmental’s PFAS Annihilator® Fit to Destroy PFAS as Outlined by New Environmental Protection Agency (EPA) Guidelines
Apr 8, 2024 12:00PM Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
Apr 3, 2024 06:00AM Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseas
Mar 28, 2024 07:00AM Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
Mar 20, 2024 06:05PM Form 3 STANDARD BIOTOOLS INC. For: Mar 18 Filed by: Viking Global Opportunities Illiquid Investments Sub-Master LP
View More Recent Stories View Older Stories